钠摄入与BENEFIT研究中多发性硬化活动及进展
该研究基于BENEFIT试验465例临床孤立综合征患者,通过5年内多次尿钠评估盐摄入,分析其与多发性硬化转化、复发、残疾及MRI活动的关联。结果显示,估计24小时尿钠水平与临床确诊多发性硬化转化、临床或MRI结局均无显著关联。
要点
- 高盐摄入未增加临床孤立综合征向多发性硬化转化的风险。
- 尿钠水平与复发率、残疾进展及MRI病灶活动均无显著关联。
- 5年多次尿钠评估支持盐摄入不影响多发性硬化疾病进程。
核心结论
- 基于5年多次尿钠排泄评估,盐摄入不影响多发性硬化的疾病进程或活动。
研究设计与样本
- BENEFIT为随机临床试验,比较早期与延迟干扰素beta-1b治疗465例临床孤立综合征患者。
- 每例患者提供中位14次(四分位距13-16)点尿样本,随访5年。
- 采用Tanaka公式估计各时点24小时尿钠排泄水平。
主要发现
- 估计每日钠摄入每增加1g,临床确诊多发性硬化风险无显著关联(HR=0.91,95%CI=0.67-1.24)。
- 6个月后新活动病灶风险无显著关联(HR=1.05,95%CI=0.97-1.13)。
- T2病灶体积相对变化无显著关联(-0.11,95%CI=-0.25至0.04)。
- EDSS变化无显著关联(-0.01,95%CI=-0.09至0.08)。
- 复发率无显著关联(HR=0.78,95%CI=0.56-1.07)。
关键数值与推荐
- 按五分位分类分析结果与连续变量分析相似。
临床怎么用
- 临床无需仅基于多发性硬化疾病活动考虑限制盐摄入。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To assess whether a high-salt diet, as measured by urinary sodium concentration, is associated with faster conversion from clinically isolated syndrome (CIS) to multiple sclerosis (MS) and MS activity and disability. METHODS: BENEFIT was a randomized clinical trial comparing early versus delayed interferon beta-1b treatment in 465 patients with a CIS. Each patient provided a median of 14 (interquartile range = 13-16) spot urine samples throughout the 5-year follow-up. We estimated 24-hour urine sodium excretion level at each time point using the Tanaka equations, and assessed whether sodium levels estimated from the cumulative average of the repeated measures were associated with clinical (conversion to MS, Expanded Disability Status Scale [EDSS]) and magnetic resonance imaging (MRI) outcomes. RESULTS: Average 24-hour urine sodium levels were not associated with conversion to clinically definite MS over the 5-year follow-up (hazard ratio [HR] = 0.91, 95% confidence interval [CI] = 0.67-1.24 per 1g increase in estimated daily sodium intake), nor were they associated with clinical or MRI outcomes (new active lesions after 6 months: HR = 1.05, 95% CI = 0.97-1.13; relative change in T2 lesion volume: -0.11, 95% CI = -0.25 to 0.04; change in EDSS: -0.01, 95% CI = -0.09 to 0.08; relapse rate: HR = 0.78, 95% CI = 0.56-1.07). Results were similar in categorical analyses using quintiles. INTERPRETATION: Our results, based on multiple assessments of urine sodium excretion over 5 years and standardized clinical and MRI follow-up, suggest that salt intake does not influence MS disease course or activity. Ann Neurol 2017;82:20-29.
引用
- Fitzgerald KC, Munger KL, Hartung HP, et al. Sodium intake and multiple sclerosis activity and progression in BENEFIT. Ann Neurol. 2017. PMID: 28556498. doi:10.1002/ana.24965
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。